Literature DB >> 7734084

Neurobiology of withdrawal motivation: evidence for two separate aversive effects produced in morphine-naive versus morphine-dependent rats by both naloxone and spontaneous withdrawal.

A Bechara1, K Nader, D van der Kooy.   

Abstract

In drug-naive rats, the rewarding effects of morphine are blocked by lesions of the tegmental pedunculopontine nucleus (TPP), but not by neuroleptics. In dependent rats (chronically treated with morphine), morphine reward is blocked by neuroleptics, but not by TPP lesions. Just as this activation of opiate receptors in naive versus dependent rats produces different mechanisms of reward, this study concludes that reduced opioid activity on these opiate receptors produces different mechanisms of aversion. Neuroleptics blocked the conditioned place aversions produced by naloxone and spontaneous withdrawal in morphine dependent, but not naive, rats, without attenuating the somatic withdrawal syndrome induced by naloxone in dependent rats. The researchers suggest that the aversive effects of endogenous opioid withdrawal in naive rats are mediated by different neural substrates than the aversive effects of exogenous opioid withdrawal in dependent rats.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7734084     DOI: 10.1037//0735-7044.109.1.91

Source DB:  PubMed          Journal:  Behav Neurosci        ISSN: 0735-7044            Impact factor:   1.912


  20 in total

1.  Comparative effects of pulmonary and parenteral Δ⁹-tetrahydrocannabinol exposure on extinction of opiate-induced conditioned aversion in rats.

Authors:  Laurie A Manwell; Paul E Mallet
Journal:  Psychopharmacology (Berl)       Date:  2014-11-15       Impact factor: 4.530

2.  Increased dopamine receptor activity in the nucleus accumbens shell ameliorates anxiety during drug withdrawal.

Authors:  Anna K Radke; Jonathan C Gewirtz
Journal:  Neuropsychopharmacology       Date:  2012-06-13       Impact factor: 7.853

3.  Episodic withdrawal promotes psychomotor sensitization to morphine.

Authors:  Patrick E Rothwell; Jonathan C Gewirtz; Mark J Thomas
Journal:  Neuropsychopharmacology       Date:  2010-09-01       Impact factor: 7.853

4.  Opiate Exposure State Controls a D2-CaMKIIα-Dependent Memory Switch in the Amygdala-Prefrontal Cortical Circuit.

Authors:  Laura G Rosen; Jordan Zunder; Justine Renard; Jennifer Fu; Walter Rushlow; Steven R Laviolette
Journal:  Neuropsychopharmacology       Date:  2015-07-15       Impact factor: 7.853

5.  Lateral hypothalamic orexin/hypocretin neurons that project to ventral tegmental area are differentially activated with morphine preference.

Authors:  Kimberlei A Richardson; Gary Aston-Jones
Journal:  J Neurosci       Date:  2012-03-14       Impact factor: 6.167

6.  Ultra-low-dose naltrexone suppresses rewarding effects of opiates and aversive effects of opiate withdrawal in rats.

Authors:  Mary C Olmstead; Lindsay H Burns
Journal:  Psychopharmacology (Berl)       Date:  2005-10-12       Impact factor: 4.530

7.  Effects of haloperidol in a response-reinstatement model of heroin relapse.

Authors:  A Ettenberg; L A MacConell; T D Geist
Journal:  Psychopharmacology (Berl)       Date:  1996-04       Impact factor: 4.530

8.  Reduced emotional signs of opiate withdrawal in rats selectively bred for low (LoS) versus high (HiS) saccharin intake.

Authors:  Anna K Radke; Nathan A Holtz; Jonathan C Gewirtz; Marilyn E Carroll
Journal:  Psychopharmacology (Berl)       Date:  2012-12-20       Impact factor: 4.530

9.  Phosphorylation of GluR1, ERK, and CREB during spontaneous withdrawal from chronic heroin self-administration.

Authors:  Scott Edwards; Danielle L Graham; Kimberly N Whisler; David W Self
Journal:  Synapse       Date:  2009-03       Impact factor: 2.562

10.  BDNF signaling in the VTA links the drug-dependent state to drug withdrawal aversions.

Authors:  Hector Vargas-Perez; Amine Bahi; Mary Rose Bufalino; Ryan Ting-A-Kee; Geith Maal-Bared; Jenny Lam; Ahmed Fahmy; Laura Clarke; Jennifer K Blanchard; Brett R Larsen; Scott Steffensen; Jean-Luc Dreyer; Derek van der Kooy
Journal:  J Neurosci       Date:  2014-06-04       Impact factor: 6.167

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.